An observational study in Graves Disease, Graves Ophthalmopathy and Mental Fatigue, sponsored by Vastra Gotaland Region. Terminated at 1 site in Sweden. Open to female participants aged 18 Years to 72 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Vastra Gotaland Region · Observational
Mental fatigue occurs in many diseases and the reasons are mostly unknown. The investigators hypothesize that remaining mental fatigue after restored hyperthyroidism in Graves' disease is an autoimmune complication. The aim of this study is to explore immunological markers possibly associated with mental fatigue in Graves' disease, which the investigators plan to validate in another study (ImmunoGraves wp 2).
Using a cross-sectional study design, mental fatigue is scored using a questionnaire to find 60 patients with and 60 without mental fatigue 15-60 months after diagnosis of Graves disease. The patients and 60 thyroid healthy controls without mental fatigue are assessed for thyroid hormones, quality of life, anxiety and depression, self-evaluated stress, coping strategies, eye symptoms and background variables. SciLifeLab in Stockholm, the national facility for autoimmune profiling, has pre-set large arrays including 42000 human proteins. Serum and cerebrospinal fluid will be separately pooled and analysed for a subgroup of patients with or without mental fatigue and for a subgroup of the control group. Proteins that preferably bind to antibodies in sera and/or cerebrospinal fluid from Graves' patients with mental fatigue in comparison to non-mental fatigue patients, will be screened against the Human Protein Atlas and the Allen brain map to identify those proteins that are expressed in the brain. Antibodies at higher concentration in the mental fatigue pools compared to the group without mental fatigue will be selected for further analyses on an individual level in the whole cohort together with antibodies targeting g-protein coupled receptors, thyroid autoantibodies, cytokines and biomarkers indicating organic and structural nerve damage.
150 studies on the registry are indexed under Graves Disease; 53 are open to participants now.
This study's enrollment of 94 is below the median of 110 across 57 observational studies indexed under Graves Disease.
Browse Graves Disease studies →Vastra Gotaland Region is the lead sponsor of 267 studies on the registry; 107 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients are recruited from the both previous patients at the Endocrine outpatient Clinic at Sahlgrenska University Hospital in Gothenburg and from advertising. They are invited to a web based screening form where the ones eligible are contacted by study personal and eligibility criteria are checked again.
Controls are recruited by the same way and by contacting a random sample from the population registration (based on Swedish social security number).
Groups are matched for age, educational level and smoking habits.
Exclusion Criteria
Women diagnosed with Graves 15 moths to 60 months ago with Mental Fatigue Scale score of more than 13 (maximum 42, cut of 10,5 for mental fatigue)
Women diagnosed with Graves 15 moths to 60 months ago with Mental Fatigue Scale score of less than 8 (maximum 42, cut of 10,5 for mental fatigue)
Women without current or previous thyroid disease and with Mental Fatigue Scale scores of less than 8
Identifying autoantibodies targeting antigens occurring in the brain that are higher in Graves' disease complicated by mental fatigue than in Graves' disease not complicated by mental fatigue
Each group will be analysed in arrays for antibodies targeting 42000 human proteins (ScilifeLabs, Stockholm). Proteins binding to antibodies in mental fatigue patients will be screened against the Human Protein Atlas (www.proteinatlas.org) and the Allen brain map (www.brain-map.org) and those expressed in the brain will be compared between groups.
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Identifying autoantibodies targeting antigens occurring in the brain that are higher in Graves' disease complicated by mental fatigue than in thyroid healthy controls without mental fatigue
Each group will be analysed in arrays for antibodies targeting 42000 human proteins (ScilifeLabs, Stockholm). Proteins binding to antibodies in mental fatigue patients will be screened against the Human Protein Atlas (www.proteinatlas.org) and the Allen brain map (www.brain-map.org) and those expressed in the brain will be compared between groups.
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Identifying autoantibodies targeting antigens occurring in the brain that are higher in Graves' disease not complicated by mental fatigue than in thyroid healthy controls without mental fatigue
Each group will be analysed in arrays for Ab targeting 42000 human proteins (ScilifeLabs, Stockholm). Proteins binding to Ab in MF patients will be screened against the Human Protein Atlas (www.proteinatlas.org) and the Allen brain map (www.brain-map.org) and those expressed in the brain will be compared between groups.
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Thyroid autoantibodies compared between Graves' disease complicated by mental fatigue, Graves' disease not complicated by mental fatigue and healthy controls
Levels of thyroid autoantibodies will be analysed with the standard method of the laboratory at Sahlgrenska University Hospital.
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Cytokines compared between Graves' disease complicated by mental fatigue, Graves' disease not complicated by mental fatigue and healthy controls
Levels of cytokines will be analysed with the standard method of the laboratory at Sahlgrenska University Hospital.
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Biomarkers indicating organic and structural nerve damage compared between Graves' disease complicated by mental fatigue, Graves' disease not complicated by mental fatigue and healthy controls
Biomarkers will be analysed with the standard method of the laboratory at Sahlgrenska University Hospital.
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Autoantibodies to other g-protein coupled receptors compared between Graves' disease complicated by mental fatigue, Graves' disease not complicated by mental fatigue and healthy controls
Levels of autoantibodies to g-protein coupled receptors will be measured using enzyme-linked immunosorbent assays
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Prevalence of endocrine ophthalmopathy in Graves' complicated by mental fatigue compared to prevalence of endocrine ophtalmopathy in Graves' not complicated by mental fatigue
Prevalence defined as endocrine ophthalmopathy that has required assessment/and or follow up at ophthalmologist.
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Self evaluated quality of life in relation to ophthalmopathy will be compared between patients with Graves' with and without mental fatigue and to healthy controls
Evaluated by the validated questionnaire the Graves' Ophthalmopathy Quality of Life Questionnaire (GO QoL).
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Self evaluated quality of life in relation to thyroid symptoms will be compared between patients with Graves' with and without mental fatigue and to healthy controls
Evaluated by the validated questionnaire Thyroid-specific Patient-Reported Outcome short-form (ThyPro 39)
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Self evaluated quality of life and well being will be compared between patients with Graves' with and without mental fatigue and to healthy controls
Evaluated by the validated questionnaire Psychological General Well Being index (PGWB)
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Self evaluated symptoms of anxiety and depression will be compared between patients with Graves' with and without mental fatigue and to healthy controls
Evaluated by the validated questionnaire the Comprehensive Psychopathological Rating Scale (CPRS).
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Self evaluated stress will be compared between patients with Graves' with and without mental fatigue and to healthy controls
Evaluated by the validated questionnaire Perceived Stress Scale (PSS-14).
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Coping strategies will be compared between patients with Graves' with and without mental fatigue and to healthy controls
Evaluated by the validated questionnaire Brief cope.
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Optimistic self-beliefs to cope with difficulties in life will be compared between patients with Graves' with and without mental fatigue and to healthy controls
Evaluated by the validated questionnaire General self efficacy.
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
Personality traits will be compared between patients with Graves' with and without mental fatigue and to healthy controls
Evaluated by the validated questionnaire NEO Five-Factor Inventory-3 (NEO-FFI-3).
Time frame: Patients and controls will be examined at one occasion, for patients 15-60 months after diagnosis of Graves' disease.
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vastra Gotaland Region